MAPK3 and prostate carcinoma: Similarly, a number of earlier investigations have demonstrated that MAPK3 expression may be a possible prognostic indicator of reduced survival in patients with malignant tumors, including breast cancer (54), oral squamous cell carcinoma (55), and prostate cancer (56) are associated with MAPK1/3.